Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TripleAXEL: Rivaroxaban vs Warfarin in Acute Ischemic Stroke with AF
NCT02042534Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rivaroxaban in ischemic stroke and Transient Ischemic Attack (TIA), sponsored by Asan Medical Center. Started Jan 2014; status: completed.
02
Drugs
rivaroxaban
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT02042534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042534.